Management of schizophrenia: clinical experience with asenapine. (Q38093729)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23535351%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

title

Management of schizophrenia: clinical experience with asenapine (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23535351%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

1 reference

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23535351%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23535351%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

Leonardo Cortese

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23535351%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

David J Castle

series ordinal

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23535351%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

language of work or name

English

0 references

publication date

27 March 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23535351%20AND%20SRC:MED&resulttype=core&format=json

Journal of Psychopharmacology

27 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23535351%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

volume

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23535351%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

issue

4 Suppl

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23535351%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

page(s)

14-22

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23535351%20AND%20SRC:MED&resulttype=core&format=json

Validation of the 16-item Negative Symptom Assessment.

27 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1177%2F1359786813482533

Typical antipsychotic drugs -- D(2) receptor occupancy and depressive symptoms in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786813482533

Depressive episodes in stable schizophrenia: critical evaluation of the DSM-IV and ICD-10 diagnostic criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786813482533

The global prevalence of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786813482533

Persistent negative symptoms in schizophrenia: an overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786813482533

Asenapine versus olanzapine in people with persistent negative symptoms of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786813482533

Psychiatric comorbidities and schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786813482533

The burden of depressive symptoms in people with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786813482533

Subjective experience and D2 receptor occupancy in patients with recent-onset schizophrenia treated with low-dose olanzapine or haloperidol: a randomized, double-blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786813482533

Asenapine elevates cortical dopamine, noradrenaline and serotonin release. Evidence for activation of cortical and subcortical dopamine systems by different mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786813482533

Antipsychotic-Induced Hyperprolactinaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786813482533

Efficacy and safety of asenapine in a placebo- and haloperidol-controlled trial in patients with acute exacerbation of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786813482533

A randomized placebo-controlled trial of asenapine for the prevention of relapse of schizophrenia after long-term treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786813482533

Catching up on schizophrenia: natural history and neurobiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786813482533

Current therapy issues and unmet clinical needs in the treatment of schizophrenia: a review of the new generation antipsychotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786813482533

Negative symptoms in schizophrenia: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786813482533

Developing therapeutics for schizophrenia and other psychotic disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786813482533

Management of the negative symptoms of schizophrenia: new treatment options

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786813482533

Noradrenergic mechanisms in the prefrontal cortex

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786813482533

Antipsychotic-induced hyperprolactinaemia, hypogonadism and osteoporosis in the treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786813482533

Serotonin receptors represent highly favorable molecular targets for cognitive enhancement in schizophrenia and other disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786813482533

Quality of life of people with schizophrenia, bipolar disorder and other psychotic disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786813482533

A systematic review of the prevalence of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786813482533

Long-term assessment of Asenapine vs. Olanzapine in patients with schizophrenia or schizoaffective disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786813482533

Asenapine: a novel psychopharmacologic agent with a unique human receptor signature

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786813482533

Alpha-adrenoceptor modulation hypothesis of antipsychotic atypicality

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786813482533

Efficacy of newer generation antipsychotics in the treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786813482533

Schizophrenia, "just the facts" 4. Clinical features and conceptualization

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786813482533